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Available online 16 September 2013This paper examines morphometry of MRI biomarkers derived from the network of temporal lobe structures in-
cluding the amygdala, entorhinal cortex and hippocampus in subjects with preclinical Alzheimer's disease (AD).
Based on template-centered population analysis, it is demonstrated that the structural markers of the amygdala,
hippocampus and entorhinal cortex are statistically signiﬁcantly different between controls and those with pre-
clinical AD. Entorhinal cortex is themost strongly signiﬁcant based on the linear effectsmodel (p b .0001) for the
high-dimensional vertex- and Laplacian-based markers corresponding to localized atrophy. The hippocampus
also shows signiﬁcant localized high-dimensional change (p b .0025) and the amygdala demonstrates more
global change signaled by the strength of the low-dimensional volume markers. The analysis of the three struc-
tures also demonstrates that the volumemeasures are only weakly discriminating between preclinical and con-
trol groups, with the average atrophy rates of the volume of the entorhinal cortex higher than amygdala and
hippocampus. The entorhinal cortex thickness also exhibits an atrophy rate nearly a factor of two higher in the
ApoE4 positive group relative to the ApoE4 negative group providing weak discrimination between the two
groups.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. 1. Introduction
Brain imaging and magnetic resonance imaging (MRI) studies have
substantially advanced our knowledge of regional brain atrophy in
Alzheimer's disease (AD). MRI measures are an indirect reﬂection of
the neuronal injury that occurs in the brain as the AD pathophysiologi-
cal process evolves. Several MRI measures are known to be altered
among individuals with AD dementia or MCI, including volumetric
MRI. In the initial stages of AD, atrophy on MRI appears to have a predi-
lection for the brain regions with heavy deposits of neuroﬁbrillary tan-
gles (Braak and Braak, 1991; Arnold et al., 1991; Price andMorris, 1999).. Open access under CC BY-NC-SA licenConsistent with this pattern of neuroﬁbrillary pathology, the volume of
the entorhinal cortex, the hippocampus and othermedial temporal lobe
structures have been shown to discriminate patients with AD dementia
versus controls, MCI subjects from controls, and to be associated with
time to progress fromMCI to AD dementia (Jack et al., 2010). Longitudi-
nal MRI data in cognitively normal individuals who have progressed to
mild impairment is extremely limited, but also suggests that volumetric
measures of medial temporal lobe regions may be useful in predicting
progression from normal cognition to mild or moderate impairment.
Differences in atrophy rate of the entorhinal cortex (Jack et al., 2004),
the hippocampus or subvolumes of the hippocampus (Jack et al.,
2004; Apostolova et al., 2010) and ventricular volume (Carlson et al.,
2008) have been demonstrated during preclinical AD. It has also
been demonstrated that baseline measures of the hippocampus and
amygdala in controls predict subsequent development ofmild cognitive
impairment (denHeijer et al., 2006). Differences in the shape of the hip-
pocampus have also been reported among controls who subsequently
developed incident cognitive impairment (Rusinek et al., 2003; Chiangse. 
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et al., 2010).
To date, manyMRI studies of subcortical graymatter nuclei have de-
ﬁned a single measure of structural volume for each subcortical struc-
ture studied. In this study we have used diffeomorphometry to deﬁne
subregional atrophy in subcortical gray matter in the entorhinal cortex,
hippocampus and amygdala. Like volumetricmeasures, statistical shape
analysis based on the diffeomorphometry allows us to transfer mor-
phometry changes across coordinate systems to template coordinates
across which statistics can be obtained in the dataset. This allows for
the detection of changes in brain structures which are not uniformly
distributed, and may be locally occurring. We examine these changes
atmultiple scales, from the highest dimension equivalent to the dimen-
sion of the vertex representation of each surface of the substructures to
the lowest dimension based on the single volume number. From these
we also calculate atrophy rates as both absolute volumes as well as a
percentage change relative to initial volume.
Methods of statistical shape analysis based on diffeomorphometry
for studying normal age related changes in subcortical nuclei and for
studying a number of other diseases have already been enlightening
(Qiu et al., 2009a, 2009b, 2010; Csernansky et al., 1998, 2000; Wang
et al., 2007; Ashburner et al., 2003; Thompson et al., 2004; Younes
et al., in press). This study focuses on differences in atrophy rates and
shape in three regions of the temporal lobe, including amygdala, hippo-
campus, and entorhinal cortex (ERC), based on earlier histopathological
ﬁndings suggesting that they may be affected during the early phase of
AD (Arriagada et al., 1992; Herzog and Kemper, 1980; Scott et al., 1991,
1992; Tsuchiya and Kosaka, 1990).
The diffeomorphometry pipeline for network shape analysis
presented here follows a general pattern that is common to several of
the referred studies, involving an initial coarse rigid alignment phase
followed by a high-dimensional template matching phase. This pro-
duces a generally high-dimensional representation of the data in a coor-
dinate system in which each coordinate is directly comparable across
shapes. In this approach all shapemorphometry is registered to a single
template coordinate system, which is centered to the population. The
statistical analysis uses standard multivariate and linear effects models,
inwhich signiﬁcance is assessedwhile takingmultiple comparisons into
account. We also examine the ERC modeled as a thin laminar structure,
enabling us to compute cortical thickness using the volume to surface
area ratio approximation for laminar thickness. Focusing on this entire
network of structures offers an opportunity to examine the onset of
morphometric changes throughout these temporal lobe structures
among those with preclinical AD.
2. Subjects and methods
2.1. Study design
The overall study (known as the BIOCARD study), is a longitudinal
characterization of individuals including structural brainmagnetic reso-
nance imaging (MRI) funded jointly by the National Institute on Aging
(NIA) and the National Institute for Mental Health (NIMH). All subjects
were cognitively normalwhen theywere recruited. Themean age of the
BIOCARD subjects at baseline was 57.1 years. Scans were acquired dur-
ing the period 1995–2005. The participants have now been followed for
up to 17 years. A total of 805 scans have been collected during the
10 year period. In this paper we report on the examination of the tem-
poral lobe circuitry including amygdala, entorhinal cortex, and hippo-
campus based on shape analysis using diffeomorphometry.
2.2. Selection of participants
A total of 354 individuals were initially enrolled in the study. Re-
cruitment was conducted by the staff of the Geriatric Psychiatry branch
of the Intramural Program of the National Institute of Mental Health,beginning in 1995 and ending in 2005. Subjects were recruited via
printed advertisements, articles in local or national media, information-
al lectures, or word-of-mouth. The study was designed to recruit and
follow a cohort of cognitively normal individuals who were primarily
in middle age. By design, approximately three quarters of the partici-
pants had a ﬁrst degree relative with dementia of the Alzheimer type.
The overarching goal was to identify variables among cognitively nor-
mal individuals that could predict the subsequent development of
mild to moderate symptoms of AD. Toward that end, subjects were ad-
ministered a comprehensive neuropsychological battery annually. Mag-
netic resonance imaging (MRI) scans, cerebrospinal ﬂuid (CSF), and
blood specimens were obtained every two years. The study was initiat-
ed at theNIH in 1995, andwas stopped in 2005. In 2009, a research team
at the Johns Hopkins School of Medicine was funded to re-establish the
cohort, continue the annual clinical and cognitive assessments, collect
blood, and evaluate the previously acquired MRI scans, CSF and blood
specimens. To the best of our knowledge, this is the only study in partic-
ipants who were cognitively normal at entry, with this set of measures,
and with such a long duration of follow-up.
At baseline, all participants completed a comprehensive evaluation
at the Clinical Center of the National Institutes of Health (NIH). This
evaluation consisted of a physical and neurological examination, an
electrocardiogram, standard laboratory studies (e.g., complete blood
count, vitamin B12, thyroid function, etc), and neuropsychological test-
ing. Individuals were excluded from participation if they were cogni-
tively impaired, as determined by cognitive testing, or had signiﬁcant
medical problems such as severe cerebrovascular disease, epilepsy or al-
cohol or drug abuse. For those with a family history of AD, autopsy re-
cords were obtained (whenever feasible) to conﬁrm the presence of
AD dementia in an immediate family member. Five subjects did not
meet the entry criteria and were excluded at baseline, leaving a total
349 participants, who were followed over time.
2.3. MRI assessments
MRI scans were obtained on 335 participants at baseline. An addi-
tional 470 scans were obtained in subsequent years for a total of 805
scans. The mean interval between scan acquisitions on follow-up
was 2.02 years. The MRI scans acquired at the NIH were obtained
using a standard multi-modal protocol using GE 1.5T scanner. The
scanning protocol included localizer scans, Axial FSE (Fast Spin
Echo) sequence (TR = 4250, TE = 108, FOV = 512 × 512, thick-
ness/gap = 5.0/0.0 mm, ﬂip angle = 90, 28 slices), Axial Flair
sequence (TR = 9002, TE = 157.5, FOV = 256 × 256, thickness/
gap = 5.0/0.0 mm, ﬂip angle = 90, 28 slices), Coronal SPGR (Spoiled
Gradient Echo) sequence (TR = 24, TE = 2, FOV = 256 × 256,
thickness/gap = 2.0/0.0 mm, ﬂip angle = 20, 124 slices), Sagittal
SPGR (Spoiled Gradient Echo) sequence (TR = 24, TE = 3, FOV =
256 × 256, thickness/gap 1.5/0.0 mm, ﬂip angle = 45, 124 slices).
2.4. Clinical and cognitive assessment
The clinical and cognitive assessments of the participants have been
described elsewhere (Albert et al., submitted). The cognitive assess-
ment consisted of a neuropsychological battery covering all major cog-
nitive domains (i.e., memory, executive function, language, spatial
ability, attention and processing speed). A clinical assessment was also
conducted annually. Since the study has been conducted at Johns Hop-
kins, this has included the following: a physical and neurological exam-
ination, record of medication use, behavioral and mood assessments
(Cummings et al., 1994; Yesavage et al., 1982), family history of demen-
tia, history of symptom onset, and a Clinical Dementia Rating (CDR),
based on a semi-structured interview(Hughes et al., 1982; Morris,
1993). The clinical assessments given at the NIH covered similar
domains.
Table 1
Participant characteristics at baseline and follow-up features stratiﬁed by outcome status.
Variable Control
group
(N = 230)
Progressed to
MCI or AD
(N = 51)
Age at entry, mean number of years (SD) 55.4 (9.8)⁎ 62.5 (11.5)⁎⁎
Gender, females (%) 60.9% 49.0%
Education, mean number of years (SD) 17.2 (2.3) 16.9 (2.4)
Ethnicity, Caucasians (%) 98.3% 94.1%
ApoE-4 carriers (%) 32.6% 33.3%
MMSE at entry, mean score (SD) 29.7 (0.7) 29.5 (0.8)
Total follow-up time, mean number of years (SD) 8.5 (3.4) 10.1 (2.6)⁎⁎
Number of MRI measures, mean per subject (SD) 2.2 (1.2) 2.3 (1.2)
MRI follow-up time, mean number of years (SD) 4.1 (2.1) 4.3 (2.1)
Abbreviations: ApoE-4, apolipoprotein E-4; MMSE, Mini-Mental State Exam.
⁎ p = .05.
⁎⁎ p = .001.
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Consensus diagnoses were completed annually at the NIH. After
the study was re-established at Johns Hopkins, the diagnostic proce-
dures have been identical to those used in the Alzheimer's Disease
Research Centers program, funded by the National Institute on
Aging. This involves a two-step process by which a decision is ﬁrst
made about whether the subject is normal, mildly impaired or de-
mented (based on the clinical history and the cognitive testing),
and then (if the subject is judged not to be normal) the likely
cause(s) of the cognitive impairment is determined. This same diag-
nostic process was applied retrospectively to participants who had
become cognitively impaired while the study was being conducted
at the NIH, but who (by the time the study had been re-established
at Johns Hopkins) were either moderate-to-severely impaired or
were no longer living. All of the members of the clinical research
team participated in the consensus diagnostic process, including:
neurologists, neuropsychologists, research nurses, and research as-
sistants. It should be noted that the estimated age-of-onset of clinical
symptoms, which is the primary outcome in these analyses, was
established on the basis of clinical information elicited during the
clinical interview by the clinician who evaluated the subject (or on
the basis of clinical notes in the record), and re-conﬁrmed during
the consensus conference.
During the acquisition of the scans at the NIH, 9 subjects were diag-
nosed with dementia of Alzheimer's type, and 8 subjects were diagnosed
with mild cognitive impairment (MCI). During that period there were a
total of 302 subjects withMRI scanswho continued to be cognitively nor-
mal. Over time, an additional number of subjects had developed MCI or
AD dementia. The focus of this paper is the subjects who were normal
when the scanswere taken but subsequently became symptomatic, com-
pared to the subjects who remained cognitively normal.2.6. MRI scans available for analysis
Of the 335 subjects with MRI scans at baseline, a total of 230 individ-
uals remained cognitively normal and 51 developed incident cognitive
impairment and were diagnosed with MCI (of these, 8 subsequently
progressed to AD dementia). The subjects who were controls at baseline
but became impaired over time are referred to here as having ‘preclinical
AD’, consistentwith a recentworking group report on this topic (Sperling
et al., 2011). Of the 230 controlswho remained controls on follow-up, 136
had repeat MRI scans (M = 2.98/subject). Of the 51 participants with
preclinical AD, 33 had repeat MRI scans (M = 2.94/subject). During the
period of MRI acquisition 17 participants received a diagnosis of MCI or
AD dementia; these subjects were not included in the analysis. In addi-
tion, 26 participants who remained controls during the MRI acquisition
phase received a diagnosis of Impaired not MCI on follow-up; these sub-
jects were not included in the analysis. A total of 18 scans had sufﬁcient
artifact that they could not be used for the present study, leaving a total
of 283MRI scans at baseline (when all participants were cognitively nor-
mal) and 333 MRI scans obtained over time (controls = 269, preclinical
AD = 64). Additionally, for the examination of atrophy rates, we only in-
cluded subjects with 3 or more MRI scans (81 controls and 20 cases of
preclinical AD). We also compared the MRI measures on the basis of the
participants ApoE4 status; the subjects with 3 or more MRI scans avail-
able for these analyses were as follows: ApoE4 positive = 44 and
ApoE4 negative = 73.
Table 1 summarizes the subjects in the two groups that were the
focus of these analyses, the controls and those with preclinical AD.
Table 2 summarizes the subjects in the same groups separated based
on their ApoE4 positive and ApoE4 negative genes. The region-of-
interest analyses described belowhave been completed for the amygda-
la, hippocampus, and entorhinal cortex for all of the subjects listed in
the columns.2.7. Surface based morphometry
Weextend the statistical analyses of diffeomorphometry followed in
previous papers (Qiu et al., 2009a, 2009b, 2010; Csernansky et al., 1998,
2000; Wang et al., 2007; Ashburner et al., 2003; Thompson et al., 2004;
Younes et al., in press) to include the temporal lobe entorhinal cortex
structure along with the amygdala and hippocampus. This procedure
has three steps: (i) segmentation of the target structures, (ii) generation
of a single template coordinate system from the population of baseline
scans, and (iii) mapping of the template onto each of the target seg-
mented structures represented via triangulated meshes. The ﬁrst step
is the segmentation of the structures for which we extend the region-
of-interest large deformation diffeomorphic metric mapping (ROI-
LDDMM) procedure described previously (Csernansky et al., 1998;
Munn et al., 2007) to the entorhinal cortex. The landmark deﬁnitions
in ROI methods are used to ensure consistency of mapping, and have
been published for amygdala and hippocampus in the aforementioned.
The entorhinal cortex is a structurewhich admits considerable variation
among protocols (Feczko et al., 2009; Honeycutt et al., 1998; Insausti
et al., 1998). Our approach for deﬁnition follows Feczko et al. (2009)
by deﬁning the lateral extent of the entorhinal cortex at the shoulder
of themedial bank of the collateral sulcus, including themaximal extent
of the entorhinal cortex as can be deﬁned in MRI over the entire length
of the hippocampal head. However our approach differs in the caudal
extent by deﬁning the caudal boundary as 2 mm posterior to the most
rostral slice showing gyrus intralimbicus (moving rostral to caudal in
coronal plane)whereas the Feczko et al. approach deﬁnes the caudal ex-
tent relative to the lateral geniculate nucleus. Landmarks were placed
on the sections uniformly along the head–tail principal axis as for the
amygdala and hippocampus, with the details of the procedure and
boundary deﬁnitions described in http://caportal.cis.jhu.edu/protocols.
Once landmarking is complete, ROI-LDDMM (landmark matching
(Joshi and Miller, 2000) and image matching (Beg et al., 2005)) are
used to generate the segmented binary volumes which were converted
into triangulated surfaces. In ROI-LDDMM the initial template used for
mapping was selected to be a smooth amygdala, hippocampus, and
ERC taken from a group of ten hand segmented sets of structures choos-
ing the initial template with average volume for the group of ten. Fig. 1
shows a view of the surface reconstructions embedded in the corre-
sponding MR imagery of one subject.
To generate shape biomarkers indexed to a common coordinate sys-
tem, we follow the procedure published in Younes et al. (in press) in
which all surfaces are rigidly aligned via rotation and translation, with
right subvolumes ﬂipped before alignment to ensure that all structures
could be compared. From rigidly aligned volumes, an average template
shape was generated based on a generative probability model over the
entire population in which the observed surfaces are modeled as ran-
dom deformations of the template (Ma et al., 2010). This template gen-
eration procedure generates coordinate systems centered to the
Fig. 1. Reconstructions of the amygdala (green), entorhinal cortex (red) and hippocampus (blue) of one subject.
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more efﬁcient than volume mapping (Ma et al., 2008). The resulting
templates for the amygdala, entorhinal cortex and hippocampus be-
come the coordinate systems which are referenced for our p-value sta-
tistics and FWER (Family-wise Error Rate) diagrams. The templates are
visualized in Fig. 2. Thesewere computed by running the template gen-
eration algorithm on the population of 325 baseline scans and are blind
to group labels. For normalization against intracranial volume (TIV), TIV
was calculated using coronal SPGR scans in Freesurfer 5.1.0 (Segonne
et al., 2004). The large sample size of 325 subjects included in this
study should outweigh any concerns about how FreeSurfer calculates
TIV (Pengas et al., 2009).
Given the template, the high-dimensional shape statistics are gener-
ated indexed to each location of the template by computing the
diffeomorphic correspondence between the template and each surface
using LDDMM surface registration (Vaillant and Glaunes, 2005). The al-
gorithmcomputes a smooth, invertiblemapping of the triangulated sur-
face template Stemp onto the target surfaces Starget minimizing the
ﬁdelity criterionmeasuring the distance between the mapped template
and target selecting the mapping minimizing the matching cost and
geodesic transformation energy (Vaillant et al., 2007; Qiu and Miller,
2008).2.8. Entorhinal cortex laminar thickness reconstruction
The entorhinal cortex is modeled as both a subvolume for morpho-
metric shape analysis as well as a thin laminar cortical structure from
which a single laminar thickness estimate is generated. First, a closedFig. 2. Template for left amygdala (green), entorhinal cortex (red) and hippocampus
(blue) template generated from the population of 173 baseline scans. All linear mixed ef-
fects model p-values reported in the tables and in the FWER visualization are computed
relative to the templates.smooth surface is generated from the segmented gray matter volume.
Then the gray/white surface is extracted from the closed surface by
curvature-based dynamic programming delineation of the extremal
boundaries (Ratnanather et al., 2003) so that the surface closest to the
white matter is retained. It was found that from about 100 closed sur-
faces, the surface area of the corresponding gray/white matter surfaces
were on average about 35.7% of that of the closed ones. So as an approx-
imation, the surface area for the entire population was calculated as
0.357 of the corresponding closed surface. In addition, the laminar
thickness is calculated as a single parameter based on the ratio of vol-
ume/surface-area in units of mm.2.9. Group based mixed linear effects statistical analysis
Weperformed statistical analyses comparing the amygdala, entorhi-
nal cortex andhippocampus subvolumes between the two groups (con-
trols vs. preclinical AD), and making separate comparisons of the shape
markers corresponding to the degree of atrophy relative to the template
between the groups. Differences between groups, based on apolipopro-
tein E4 genotype (ApoE4) were also examined. We model the shape
markers via linear and mixed effects modeling. The linear model previ-
ously used in Younes et al. (in press) takes the absolute volume and at-
rophy rate of the linear model as a function of age as different between
the two groups, denotedα þ α′age;β þ β′age. Themixed effects as used
by Bernal-Rusiel et al. (2012) corresponds to representing the noise in
themeasuring shapemarker as corresponding to two different process-
es, one associated to the time series within a subject, and the second
noise associated to the cross-sectional variation from subject to subject.
The analysis includes age, gender and log intracranial volumes as covar-
iates, and computes statistics at each vertex of the triangulated template
surface returning p-values corrected for multiple comparisons using
permutation testing (Nichols and Hayasaka, 2003).
The analysis uses amixed linear effects model for each vertex v, scan
j and subject s. For this, each subject's left and right structures (controls
and patients) has been registered to the template, resulting in the com-
putation of a normalized deformation marker yvj(s) measuring how
much expansion/atrophy at vertex v of the template surface in register-
ing it to subject s for scan j. The raw expansion/atrophy measure is de-
ﬁned as the logarithm of the local expansion/reduction in surface area
around the vertex, interpreted mathematically as a log-jacobian on
the template surface. This measure is then normalized for variations
due to gender and intracranial volume by ﬁtting a linear regression
model that predicts the former by the latter, and taking the residual,
yielding yvj(s). This normalization is group independent.
Table 2
Participant characteristics at baseline and follow-up features stratiﬁed by apolipoprotein E
(ApoeE) status.
Variable ApoE-4 present
(N = 39)
ApoE-4 absent
(N = 62)
Age at entry, mean number of years (SD) 56.9 (6.4)⁎ 58.1 (10.0)⁎⁎
Gender, females (%) 71.8% 59.7%
Education, mean number of years (SD) 17.2 (2.2) 16.8 (2.7)
Ethnicity, Caucasians (%) 97.4% 98.4%
MMSE at entry, mean score (SD) 29.7 (0.8) 29.6 (0.7)
Total follow-up time, mean number of years (SD) 11.3 (2.5) 11.0 (2.7)
Number of MRI measures, mean per subject (SD) 3.6 (0.8) 3.6 (0.7)
MRI follow-up time, mean number of years (SD) 5.3 (1.8) 5.4 (1.6)
Abbreviations: ApoE-4, apolipoprotein E-4; MMSE, Mini-Mental State Exam.
⁎ p = .05
⁎⁎ p = .001.
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to the preclinical AD group and zero if the subject belongs to the control
group. Our deformation marker model is given by the equation
yvj sð Þ ¼ αv þ α′va j sð Þ
 
þ βv þ β′va j sð Þ
 
g sð Þ þ εvj sð Þ ð1Þ
where the notation is as follows:
• yvj(s) is the deformationmarker for subject s at scan j, with v indexing
the vth vertex of the deformation marker (or one of the 25 Laplace
Beltrami coefﬁcients or a single log-volume), after correction for intra-
cranial volume and gender. Correction is done by taking residuals
after least-squares linear regression of the shape variables by the co-
variates;
• aj(s) is the subject's age at scan j;
• g(s) is the subject's group (g = 0 for control, g = 1 for disease);
• εvj(s) represents the noise, and is modeled as εvj(s) = ηv(s) + ζvj(s)
where ηv(s) is a “random effect” that measures between-subject var-
iation and ζvj(s) measures within-subject variation. Both processes
are assumed to be centered Gaussian, with variance ρvσv2 and σv2,
respectively.
Parameters θν ¼ αv;α′v;βv;β′v
 
;σ2v and ρv are estimated by
maximum-likelihoodwith the estimation procedure derived in the sup-
plement. We test for the null hypothesis withH0v : β
′
v ¼ βv ¼ 0 for all v,
while correcting for multiple comparisons. For volume testing the loga-
rithm of the volume is used because it is appropriate for the additive
noise model. The p-values of these models are computed using permu-
tation sampling (Nichols andHayasaka, 2003) runninguntil 10% accura-
cy is reachedwith high probability. The test statistic is the log-likelihood
difference between the null hypothesis H0v : β
′
v ¼ βv ¼ 0 and the alter-
native general hypothesisH1v : βv;β
′
v
 
≠ 0;0ð Þ computing for all verti-
ces the statistic
Sv ¼ LH1v −LH0v : ð2Þ
The parametersαv;α′v;βv;β
′
v;σ2v are estimated bymaximum likeli-
hood for all dimensions v for each of the two hypotheses. Evaluating the
log-likelihood in each case at the MLE's of the parameters gives the log-
likelihood essentially determined by the mixed sums of squares as
shown in the supplement.
The joint test statistic is computed fromEq. (2)with family-wise error
rates (FWER) calculated by evaluating the maximum S∗ = max vSv. p-
Values are computed using permutation sampling running until a 10%
accuracy is reachedwith high probability. Themaximum value S∗ is com-
pared to those obtained by performing the same computation a large
number of times, with group labels randomly assigned to subjects. The
p-value is given by the fraction of times the values of S∗ computed after
permuting the labels is larger than the value obtained with the true
groups. The p-values that were observed via the linear effects modeling
of deformationmarkers of Eqs. (1), (2) are provided, for each structure in-
cluding the left and right sides of the brain in Table 5. The volume statis-
tics shown in column 4 of Table 5 for the three groups provides p-values
for the same linear effects model, also evaluated via permutations, in
which y is replaced by the structure volume, forwhich nomultiple testing
correction is required. This permutation testing procedure also provides a
(conservative) estimate of the set of vertices v onwhich the null hypoth-
esis is not valid. This set is deﬁned byD = {v : Sv ≥ q∗}where q⁎ is the 95
percentile of the observed value of S∗ over the permutations (Nichols and
Hayasaka, 2003). Figs. 4 and 5 illustrate the vertex markers on the ento-
rhinal cortex thatwere signiﬁcant, coloring these verticeswith an atrophy
measure deﬁned as− βv þ β′vage
 
, whereβv;β
′
v are the coefﬁcients as-
sociated to the group variable in the regressionmodel for vertex v, andage
is the average age in the preclinical AD population. We also performed a
similar analysis based on the decomposition of the deformation marker
y(s) over the orthonormal basis formed by the eigenvectors of theLaplace–Beltrami operator on the template surface (Miller and Qiu,
2009).We used the 25ﬁrst eigenvectors and followed the same statistical
construction in which the original marker y(s) is replaced by its 25-
dimensional projection on the basis. Results from this procedure are
also reported in Table 4.
3. Results
Table 3 shows the rates of atrophy for linear ﬁts of the amygdala,
hippocampus and entorhinal cortex volumes as a function of scan num-
ber for the controls and the preclinical AD subjects. For ﬁtting the atro-
phy rates, the samplewas censored so as to include subjectswhose time
series contained three or more scans but was not normalized by intra-
cranial volume covariates.We see the amygdala atrophy rate increasing
from .6% to nearly 1.2% per-year from control to preclinical AD groups,
and the entorhinal cortex atrophy rate from 1.0% to 2.7%. The atrophy
rate of the thickness of the entorhinal cortex also increases from 0.33%
in controls to 1.04% in the preclinical AD cases. Also, we see an increase
in atrophy rate nearly doubling in the ApoE4-positive relative to ApoE4-
negative groups in the thickness of the entorhinal cortex. Interestingly,
the atrophy rate of the entorhinal cortex of 1.0% in the control groups is
two to three times the control atrophy rates of the amygdala and
hippocampus.
We tested on the volume based atrophy rates percentages of the
amygdala, the hippocampus and the entorhinal cortex, with the
resulting p-values shown in Table 3 generally showing weakly signiﬁ-
cant differences between the controls versus preclinical AD. The thick-
ness of the entorhinal cortex was also weakly signiﬁcantly different in
ApoE4-positive versus ApoE4-negative subjects when studied bilateral-
ly (p = .03).
Fig. 3 visualizes localized atrophy in volume across the left amygdala,
entorhinal cortex, and hippocampus as percentage decrease (Jacobian)
between the control population and the preclinical AD population. The
average template shape was created for each of the control and preclin-
ical AD groups representing the centers of the population. Shown on the
control group template is the surface Jacobian of the diffeomorphism
mapping one population to the other. The color scale indicates atrophy
deformation change for the Jacobian on the scale of 0.8–1.
We nowpresent the p-value statistical results thatwere obtained for
the template based morphometry linear effects model analyses of
Eqs. (1), (2) quantifyingmorphometric change locally across the amyg-
dala, hippocampus, entorhinal cortex template coordinate systems for
the preclinical cohort. Table 5 shows the p-value signiﬁcance between
the groups and substructures, for the controls versus the preclinical
cases. Signiﬁcance is shown as measured in order of parametric dimen-
sion, with vertex-based change the highest order of 750–1000 dimen-
sions per structure, the Laplacian representation of 25 dimensions per
structure, and volume only one dimension per structure. Our general
ﬁndings are that signiﬁcance increases as a function of dimension,
with volume based testing the least powerful in terms of signiﬁcance.
Table 3
Annualized atrophy rates for normal group and preclinical AD group.
Groups Amygdala
mm3/year
Amygdala %/year Hippocampus
mm3/year
Hippocampus
%/year
ERC mm3/year ERC %/year ERC thickness
mm/year
ERC thickness %/year
L controls (n = 81) 4.6 ± 39.1 0.2 ± 2.7 14.0 ± 25.2 0.5 ± 0.9 4.9 ± 19.8 0.8 ± 4.3 .008 ± 0.043 0.34 ± 1.89
L preclinical (n = 20) 16.8 ± 25.3 1.0 ± 1.6 14.4 ± 29.1 0.5 ± 1.1 8.1 ± 15.3 1.7 ± 3.2 .022 ± 0.050 0.92 ± 2.20
L ApoE4+ (n = 44) 4.9 ± 45.3 0.2 ± 3.2 12.9 ± 29.6 0.6 ± 1.0 4.8 ± 20.8 0.7 ± 4.6 .019 ± 0.047 0.76 ± 2.02
L ApoE4− (n = 73) 8.2 ± 32.4 0.4 ± 2.1 11.9 ± 24.3 0.4 ± 0.9 5.1 ± 19.5 0.5 ± 6.5 .004 ± 0.054 −0.01 ± 3.22
R controls (n = 81) 14.2 ± 29.8 0.9 ± 2.0 21.2 ± 31.8 0.9 ± 1.9 5.5 ± 19.7 0.9 ± 4.2 .007 ± 0.039 0.28 ± 1.78
R preclinical (n = 20) 22.0 ± 27.1 1.4 ± 1.8 4.6 ± 28.5 1.1 ± 1.4 13.2 ± 19.2 3.3 ± 3.8 .024 ± 0.040 1.08 ± 1.79
R ApoE4+ (n = 44) 14.5 ± 28.6 1.0 ± 2.0 20.8 ± 33.4 0.8 ± 1.8 8.4 ± 24.1 1.6 ± 4.9 .014 ± 0.047 0.60 ± 2.10
R ApoE4− (n = 73) 16.7 ± 37.1 1.0 ± 2.4 14.5 ± 30.4 0.9 ± 2.3 4.3 ± 17.3 0.6 ± 4.7 .001 ± 0.040 −0.03 ± 2.18
B controls (n = 81) 9.4 ± 27.6 0.6 ± 1.8 17.6 ± 22.4 0.7 ± 0.9 5.2 ± 14.8 1.0 ± 3.3 .008 ± 0.031 0.33 ± 1.42
B preclinical (n = 20) 19.4 ± 19.2 1.2 ± 1.2 9.5 ± 20.6 0.3 ± 0.8 10.6 ± 14.4 2.7 ± 3.1 .023 ± 0.039 1.04 ± 1.73
B ApoE4+ (n = 44) 9.7 ± 29.4 0.6 ± 2.0 16.9 ± 25.1 0.7 ± 0.9 6.6 ± 16.2 1.3 ± 3.4 .016 ± 0.034 0.71 ± 1.48
B ApoE4− (n = 73) 12.5 ± 30.0 0.7 ± 1.9 13.2 ± 20.7 0.5 ± 0.8 4.7 ± 15.9 0.6 ± 5.5 .002 ± 0.042 0.01 ± 2.47
The table presents the volume atrophy rates and standard deviations in % and mm3/year for amygdala (columns 2 and 3), hippocampus (columns 4 and 5) and entorhinal cortex (ERC)
(columns 6 and 7), for time series with at least 3 scans. The top group of four rows is for L = Left; themiddle group of four rows is for R = Right; the bottom group of four rows is for B =
Bilateral; three preclinical subjects with hippocampal volume atrophy rates were outliers and were removed.
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niﬁcant based on the linear effects model using both of the subsets of
the high-dimensional vertex and Laplacian-based markers for the con-
trols vs. those with preclinical AD. Notice that many of the high-
dimensional markers (vertex and Laplace) show strongest signiﬁcance,
with the vertex markers b .0001 for the preclinical AD group. This im-
plies more localized change is signiﬁcant in the entorhinal cortex. This
can be contrasted with the amygdala which is also signiﬁcant, but dem-
onstrates more global change signaled by the strength of the low-
dimensional markers. The hippocampus is also signiﬁcant between
the groups, but only associated to the high-dimensional vertex markers
implying locality of change in these preclinical groups. The high-
dimensional vertex and Laplacian markers imply the entorhinal cortex
is the earliest signaler of the disease.
Diffeomorphometry allows for the detection of the anatomical re-
gions within the subcortical structures, which carry the discriminating
information between groups. Figs. 4 and 5 respectively, visualize the
vertex coordinates on the left and right template entorhinal cortex in
the linear mixed effect model for the group-wise analysis. The topFig. 3.A visualization of atrophy on the left amygdala, entorhinal cortex, and hippocampus
as percentage decrease (Jacobian) in volume between the control population and the pre-
clinical population. The transformation whose Jacobian is shown is a diffeomorphism be-
tween a template centered to the control group, and a template centered to the preclinical
group. The surface that the Jacobian is visualized on corresponds to the control group
template.panel of Fig. 4 shows image intensity on the templates which is propor-
tional to atrophy level, given by β þ β′age
 
, where age is the average
age in the study and β, β′ are estimated according to the model of
Eqs. (1), (2) using maximum-likelihood estimation (see Supplement)
with a parameter value at each vertex. These values are all positive, in-
dicating that group difference is only associated to atrophy. The range of
volume decrease as measured by the Jacobian is 0.8 to 1. The bottom
panel shows only the vertices on the surfaces of the templates which
are statistically signiﬁcant for atrophy as measured by the permutation
testing, demonstrating statistically signiﬁcant change for the controls
versus the preclinical AD cases based on family wise error rates
FWER = 5%. Non-signiﬁcant vertices have zero intensity. These are
the vertices which give rise to the vertex p-value statistic in the table
of b .0001 for the entorhinal cortex. We have placed the template back
into its relative position in an actual brain so that the statistical re-
sponses on the template structures can be seen relative to the others
(Table 5).
4. Discussion
MRI measures of the amygdala, hippocampus and entorhinal cortex
based on both volume and template-centeredmorphometric population
analysis demonstrate that there are statistically signiﬁcant differences
between controls and subjects with preclinical AD. With respect to the
localized morphometric analyses, the entorhinal cortex is the most
strongly signiﬁcant based on the linear effects model (p b .0001 left,
p = .0067 right) for the high-dimensional surface-based vertex mea-
sures signaling localized atrophy. The hippocampus shows signiﬁcantTable 4
p-Values for annualized atrophy rates comparing normal group vs preclinical AD group.
Groups Side p-value
atrophy
rate
Amygdala
p-value
atrophy
rate
Hippocampus
p-value
atrophy rate
ERC
p-value
atrophy
rate ERC
thickness
Control vs
Preclinical AD
Left 0.046 0.486 0.161 0.145
Right 0.157 0.3304 0.011 0.041
Bilateral 0.042 0.07 0.021 0.050
ApoE4+ vs
ApoE4−
Left 0.324 0.155 0.420 0.059
Right 0.462 0.329 0.144 0.062
Bilateral 0.382 0.084 0.208 0.030
The table shows the p-value testing on rate of change resulting from linear ﬁtting of vol-
umes for control versus preclinical AD groups (row 2), and ApoE4 positive versus ApoE4
negative groups (row 3) for amygdala (column 3 showing left, right, bilateral), hippocam-
pus (column 4 showing left, right, bilateral) and ERC volume and thickness (columns 5, 6
respectively).
Fig. 4. Top: atrophy visualization in left entorhinal cortex asmeasured by linear effectsmodel ﬁt− βv þ β′vage
 
evaluated at average age of natural log of Jacobian of atrophy and atrophy
ratedemonstrating percentage decrease of control to preclinical group. Bottom: statistically signiﬁcant vertices at 5% FWER.
358 M.I. Miller et al. / NeuroImage: Clinical 3 (2013) 352–360localized high-dimensional change (p = .022 left, p b .0025 right). The
amygdala shows signiﬁcance for localized high-dimensional change
(p = .031 right). This is consistent with the hypothesis that the ERC is
more affected in the early onset of the disease than the other structures.
Interestingly, only the amygdala demonstrates globalmorphometric vol-
ume change signaled by the strength of the low-dimensional volume
markers (p = .0086 left, p = .0043 right).Fig. 5.Top: atrophy visualization in right entorhinal cortex asmeasuredby linear effectsmodelﬁt o
demonstrating percentage decrease of control to preclinical group. Bottom: shows statistically sigAtrophy rates based on linear ﬁts to the volume measure for the
three structures showed that the annual atrophy rate of the total vol-
ume of the entorhinal cortex, the total volume of the amygdala and
the right hippocampus is greater in the preclinical AD group vs the con-
trols. The average rate of atrophy of entorhinal cortex is higher than that
of the amygdala or the hippocampus. Additionally, the atrophy rate of
the entorhinal cortex thickness in the ApoE4-positive group was nearlyf natural log of Jacobian of atrophy and atrophy rate evaluated at average age− βv þ β′vage
 
niﬁcant vertices as measured by permutation testing at 5% FWER.
Table 5
Morphometry measures comparing normal group vs preclinical AD group.
Structures
examined
p-Values based on
vertex measure
Control vs.
preclinical AD
p-Values based on
Laplace measure
Controls vs.
preclinical AD
p-Values based on
volume measure
Controls vs.
preclinical AD
Amygdala (L) 0.17 0.13 0.0086
Hippocampus (L) 0.022 0.33 0.073
ERC (L) b0.0001 0.0001 0.51
Amygdala (R) 0.031 0.029 0.0043
Hippocampus (R) 0.0025 0.08 0.79
ERC (R) 0.0067 0.0003 0.17
The table presents the p-values resulting from linearmixed effects models testing controls
versus preclinical AD based on the Vertex (column 2), Laplace Beltrami (column 3) and
Volume (column 4) morphometry measures. Columns list p-values for the vertex (750–
1000 dimensions per structure), Laplace (25 dimensions) and volumemarkers (1 dimen-
sion per structure).
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between the two groups (p b .03).
The ERC volume ﬁndings are largely consistent with previous re-
ports, and demonstrate the substantially greater rate of change in ento-
rhinal cortex volume during preclinical AD, as compared with the other
two structures amygdala and hippocampus. The template-based mor-
phometry ﬁndings showing localized shape change in the entorhinal
cortex are consistent with histological ﬁndings indicating that AD be-
gins to manifest itself in the entorhinal cortex (Gomez-Isla et al.,
1996). The transentorhinal region referred to by Braak and Braak,
1991 connects to the lateral boundary that shows signiﬁcant atrophy
in these analyses, as shown in Fig. 4 (left) and 5 (right).
A differential rate of change in the entorhinal cortex, as compared to
the hippocampus, has previously been reported among individualswith
MCI who subsequently progressed to AD dementia (Du et al., 2001;
Dickerson et al., 2001; Jagust et al., 2006; Du et al., 2006; Jack et al.,
2010). Our ﬁndings indicate that this differential rate of change also per-
tains to individuals with preclinical AD.
Localized template-based differences in morphometry representing
localized alterations in shape of the entorhinal cortex and amygdala
during preclinical AD have not, to our knowledge, been previously re-
ported. The ﬁnding with regard to the hippocampus is consistent with
our previous report in a separate group of subjects with preclinical AD
(Csernansky et al., 2005).
The ﬁndings with regard to the amygdala are consistent with volu-
metric changes, as well as non-uniform shape changes, which have
been reported in symptomatic AD, such as the volume changes noted
in (Poulin et al., 2011) and recent shape analysis by Cavedo et al.
(2011) and Qiu et al. (2009b) which used similar morphometric ap-
proaches applied to parcellated subﬁeld atlases.
These ﬁndings warrant further investigation in several directions.
Despite the small rise, atrophied subregions of the amygdala, entorhinal
cortex and hippocampus could be detected with p-values based on
family-wise error rates which, unlike false discovery rates, have the ad-
vantage of not requiring additional assumptions on the data such as in-
dependence or positive dependence. Such approaches also present the
possibility of direct estimation of onset times of the disease within the
temporal lobe structures providingdirect estimateswithin the temporal
lobe structures of the progression of the disease.
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